Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma

Affiliations

• ¹ Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, Calif. Electronic address: jcorren@ucla.edu.
• ² Department of Medicine, National Jewish Health, Denver, Colo.
• ³ Department of Medicine, Yale School of Medicine, New Haven, Conn.
• ⁴ Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Md.
• ⁵ Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden.
• ⁶ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.
• ⁷ Global Medical Affairs, Amgen, Thousand Oaks, Calif.
• ⁸ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.